Articles tagged with Cancer Patients
The WINTHER trial successfully matched personalized therapy to 35% of patients with advanced cancer, showing improved overall survival for those with a high degree of matching. The trial's strategy employed RNA expression testing to tailor treatment based on gene expression differences between tumors and normal tissues.
Researchers have uncovered a new set of rules that predict how the tissue of origin influences tumor genetic makeup, with potential implications for targeted cancer therapies. The study found that cancer cells are addicted to specific NAD synthesis pathways, making them vulnerable to targeted interventions.
A study found that poor air quality significantly increases the risk of hospitalizations for respiratory issues in young cancer survivors, particularly those who received chemotherapy. The researchers tracked nearly 4,000 survivors and found that even low levels of PM2.5 can contribute to respiratory problems.
Researchers found that patients with cancer requiring emergency department care had lower admission rates and higher mortality rates at non-cancer center hospitals. This may be due to a lack of cancer expertise and missed markers of worsening disease.
A recent study found that 40.3% of people with cancer used marijuana in the past year, compared to 38.0% without cancer. Meanwhile, prescription opioid use was higher among those with cancer (13.9%) than without (6.4%).
Researchers found that treating patients with personalized, combination therapies improved response rates and overall survival in patients with therapy-resistant cancers. Highly matched patients showed a 50% response rate compared to unmatched or less well-matched patients.
A breakthrough CRISPR gene-editing tool allows for the simultaneous execution of multiple edits in DNA extracted from human cells. This technology, developed by the Gene Editing Institute and licensed to NovellusDx, can rapidly reproduce an individual patient's cancer tumor genetic features and identify driver mutations.
Acute myelogenous leukemia patients have only a one in four chance of survival after five years. Researchers created a protein atlas to identify and classify protein signatures at AML diagnosis. The online atlas helps recommend better treatment and personalized medicine for patients.
A new approach, PRO-cision Medicine, uses patient-reported outcomes to personalize cancer care. This method provides valuable information on patients' symptoms and functioning, guiding clinicians in making informed decisions.
A new algorithm can detect the molecular signature of a cancer-driving defect, identifying patients who could benefit from treatment with PARP inhibitors. The algorithm has the potential to expand greatly the pool of patients eligible for this therapy.
A consortium of researchers identified a rare but important gene target, NRG1, responsible for development of various cancer types. The study suggests that targeting this gene fusion could effectively shut down cancers, offering a new therapy possibility.
A new American Cancer Society study highlights the need to better identify patients with metastatic cancer who may not benefit from aggressive treatment. The study found wide variations in treatment patterns among patients who died within a month of diagnosis.
One-third of cancer patients use complementary and alternative medicines such as meditation, yoga, acupuncture, and herbal supplements. Many patients do not disclose their use to doctors due to lack of knowledge or perceived need for disclosure.
A nationwide survey found that 33.3% of cancer patients used complementary and alternative medicines, with herbal supplements being the most common. Many participants did not disclose their CAM use due to lack of physician inquiry or perceived unnecessary information.
A small clinical trial suggests that high-dose vitamin D may delay disease progression in patients with metastatic colorectal cancer. Patients who received high-dose vitamin D had a median delay of 13 months before their disease worsened, compared to 11 months for those in the low-dose group.
A new surgical guideline has been shown to decrease re-operation rates for breast cancer patients undergoing lumpectomy. According to a study by UBC medical student Alex Monaghan, women with early-stage breast cancer are now 72% less likely to require additional surgery.
Scientists visualized CAR T cells fighting blood cancer for the first time, revealing key interactions and behaviors. The study showed that CAR T cells can directly kill tumor cells within minutes, but their effectiveness is hindered by aggregation and infiltration issues.
A new study found that continued smoking by patients with cancer adds significant costs to subsequent cancer treatment. The analysis conservatively suggests a total of nearly $11,000 in increased treatment costs for each smoking patient after their initial cancer treatment fails.
A study published in JAMA Network Open found that continued smoking after a cancer diagnosis increases the risk of cancer treatment failure and adds $11,000 to treatment costs per patient. The research estimates $3.4 billion in national additional cancer treatment costs if patients continue to smoke.
Researchers found that Chop expression is higher in T cells from ovarian cancer patients, and high nuclear levels of Chop are associated with poor clinical responses. Blocking Chop or ER stress may help improve T cell-based immunotherapy treatments.
Metastatic cancer survivors face unprecedented challenges, including psychosocial burdens, financial strain, and emotional struggles. Experts like Terry Langbaum and Thomas Smith advocate for studying this population and improving care management to ease their journey.
Cancer research highlights canine sniffing detection, spicy compound slowing lung cancer progression. Neurodegenerative diseases examined via gum bacteria link to Alzheimer's and Parkinson's. New therapies target diabetes complications and liver failure.
Researchers at Medical College of Georgia found that higher levels of CCR4 gene are associated with better survival rates and longer lifespan in patients with colorectal cancer. The gene helps the immune system differentiate between good cells and bad cells.
Researchers found that rucaparib reduced tumor size and controlled growth in 17 out of 19 patients with BRCA1, BRCA2, or PALB2 mutations. The study provides promising early evidence for this approach as a less toxic option.
A phase I clinical trial and FDA expanded access program show LOXO-195, a next-generation TRK inhibitor, is safe and effective in patients with NTRK gene fusions resistant to first-generation TRK inhibitors. The study found that LOXO-195 induced responses in patients whose tumors had acquired specific mutations.
A prototype wearable device can continuously collect live cancer cells directly from a patient's blood, offering a biopsy alternative. This innovation could help doctors diagnose and treat cancer more effectively by providing better information for planning treatments.
A combination of ipilimumab and nivolumab has been shown to shrink tumors in patients with high-grade neuroendocrine carcinoma by 42 percent, while all low-grade patients did not see a response.
A new combination of immunotherapy and chemotherapy has caused tumors to shrink in 83% of patients with metastatic pancreatic cancer. The treatment, involving a CD40 antibody, checkpoint inhibitor, and standard-of-care chemotherapy, showed manageable side effects, suggesting a durable response.
A study suggests that increasing T cells' exposure to potassium, mimicking high potassium levels, could make cancer immunotherapies more effective. Growing T cells under conditions of high potassium preserves their stem-cell-like quality, allowing them to replicate and grow.
Dr. Daniel Von Hoff, TGen's Physician-In-Chief, has been recognized for his exceptional clinical research contributions through the Methods in Clinical Cancer Research Workshop, educating 100 students each summer. The workshop has trained nearly 2,300 graduates, who now populate leading cancer centers nationwide.
A new study found that cancer patients use more potent forms of medical marijuana with higher amounts of tetrahydrocannabinol (THC), relieving symptoms and side effects of cancer treatment. Non-cancer patients, on the other hand, prefer CBD-rich formulations for their therapeutic benefits.
A new study finds that preventive medications, such as those for blood pressure and bone health, are frequently continued until death in older adults with cancer. The use of these medications can increase the risk of serious side effects and reduce quality of life.
A recent publication touted genetic risk scores as a tool for identifying patients at high risk of heart disease, cancer, and diabetes. However, a new study questions the value of these scores, finding they have lower accuracy when considering individual patient factors.
Researchers from University of Surrey investigated public attitudes towards new Faster Diagnosis Standard (FDS) for Cancer, finding participants valued reassurance and support from GPs as highly as speedy referrals. GPs will need clear guidance to support patients under the new standard.
Researchers from University of Texas Medical Branch at Galveston developed a laser treatment that selectively destroys cancerous prostate tissue while preserving erectile and urinary functions. This technique is shown to be as effective as complete removal or radiation therapy with improved quality of life.
Researchers developed a non-invasive MRI methodology to determine if tumours have invaded lymph nodes prior to surgery. This innovation helps clinicians choose optimal treatment strategies and reduces overtreatment risks. By improving accuracy, SPI may also aid in selecting patients for pre-operative radiation and chemotherapy.
LumosVar is a computer program that can accurately identify cancer-causing genetic variants from patient tumor samples. The tool helps physicians determine individualized treatment for patients by differentiating normal DNA from mutated and cancerous DNA changes.
A recent study by Cancer Research UK reveals that African-American cancer patients with inherited red blood cell conditions are 20% more likely to experience serious adverse events. This disparity may be attributed to the rigors of therapy and the disproportionately higher incidence of these disorders in the African-American population.
Researchers have identified GARP, a protein on immune cells, as a potential new target for immunotherapy against colorectal cancer. Disrupting GARP reduces tolerance and inhibits Treg cell migration to the gut, leading to reduced colon cancer development.
A new study reveals that patients with prostate, bladder, or kidney cancers who have had psychiatric care prior to treatment are at a greater risk of dying. The research also found an increased suicide risk among these patients, even after adjusting for previous mental health treatment.
A new study shows that innovative communication programs can improve patients' mental health symptoms and quality of life. The program, which involves structured conversations between clinicians and patients, results in more timely and meaningful discussions about patient values and goals.
Researchers from German Cancer Research Center have successfully reconstructed biomolecules in their mirror-image form. This breakthrough could lead to the creation of mirror-image therapeutic proteins that are protected from biological breakdown and do not provoke immune responses.
Two new studies highlight advances in lung cancer treatment. A multidisciplinary thoracic cancers symposium presents findings on local consolidative therapy linked to improved overall survival for patients with oligometastatic non-small cell lung cancer (NSCLC). Another study demonstrates the effectiveness of structured exposure to NSC...
Researchers at the University of Pittsburgh and UPMC Hillman Cancer Center have developed an AI model that can accurately identify benign nodules in low-dose CT scans, reducing false positives by up to 30%. This means patients with benign nodules won't need additional testing or biopsies, streamlining their care.
Researchers have identified two new nuclear medicine tracers that provide high-contrast images for cancer diagnosis, allowing for shorter imaging times and no diet changes. The tracers target cancer-associated fibroblasts, promoting tumor growth, migration, and progression.
A team of Australian and US researchers has identified a potential therapeutic drug target for aggressive breast cancers. The Oncomix method enabled them to 'zoom in' on genetic information from cancer patients and identify genes with distinct activity patterns, revealing five genes that promote tumour growth.
Researchers have discovered a potential treatment for cancer in patients with epidermolysis bullosa, a severe skin disease also known as butterfly disease. The new drug, rigosertib, was shown to be highly effective at killing cancer cells in preclinical studies and may target the cancer without harming healthy cells.
A study of over 675,000 cancer patients found that those with a psychiatric history were 73% more likely to die from their cancer. The risk increased with the level of psychiatric help, suggesting that stress may affect the body's biological systems.
Researchers at Huntsman Cancer Institute discovered a combination drug therapy that may effectively combat the disease. The study, led by Conan Kinsey and Martin McMahon, found a strong response in mouse models and may be a promising therapy for patients with pancreatic cancer.
Stem cell research reveals that aging brain stem cells enter a state of dormancy promoted by inflammatory signals, reducing their ability to regenerate neurons. However, blocking these inflammatory signals using antibodies increases dividing activity and improves neuron production.
Scientists at FAU create porous scaffolds using electrospinning to support ovarian follicle growth, showing promising results. The goal is to develop an ideal artificial ovary that mimics the natural environment for follicle maturity, potentially increasing fertility in cancer patients.
A new study by Colorado researchers finds that group dynamics-based exercise class increases quality of life beyond personal training for breast cancer survivors. Both groups showed similar physical gains, but the women in the group-dynamics class outpaced those in personal training.
A study of 160 breast cancer survivors found that most reported four times more positive than negative thoughts about changes they experienced due to their illness. Patients who participated in a psychological intervention program reported even more positive life changes.
Researchers found that mutations in cancer genes disrupt regulatory links between unicellular and multicellular genes, leading to widespread downstream dysregulation. The study provides a novel framework for identifying key mutations in cancer cells.
Researchers at the University of Kansas have developed a 'lab-on-a-chip' that can detect cancer in a minuscule amount of plasma, leading to timelier interventions and better outcomes for patients. The device uses a 3D nanoengineering method to mix and sense biological elements more efficiently, enabling faster and cheaper detection.
The proportion of early-stage drug trials tackling rare cancer types has increased sharply, with the analysis highlighting a changing treatment landscape. New molecularly-targeted anticancer drugs and immunotherapy are being evaluated for less common tumour types.
Researchers at UVA School of Medicine discovered a defect in killer T cells that makes them ineffective against cancer. Repairing this defect could make the cells better cancer killers.
A new AI using Network Analysis has identified nausea as a central symptom impacting various networks of cancer symptoms during chemotherapy. This analysis could help plan treatment and manage symptoms for future patients.
The growing number of cancer survivors, particularly those over 65, poses a significant challenge in delivering follow-up care due to their multiple health issues. Risk-stratified cancer follow-up care is recommended as a solution to address the supply and demand gap.
A preclinical study has identified a potential treatment strategy for low-grade gliomas, a common and lethal form of brain tumor. The researchers found that certain mutations in genes IDH1, TP53, and ATRX make glioma cells less aggressive and resistant to radiation therapy.